Contents of this document
Earnings presentation materialsSecond quarter of the fiscal year ending March 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥192 million
Operating profit¥-495 millions operating loss
Ordinary income¥-483 million ordinary loss
Net income-483 Millions of yen net loss attributable to owners of the parent
Selling, general and administrative expenses¥610 million; selling, general and administrative expense ratio to revenue: not_disclosed
Full-year earnings forecast
Net Sales
¥590 million
Operating loss
¥-895 million
Ordinary loss
¥-883 million
Net loss attributable to owners of the parent
¥-889 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing broadly in line with the planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in CDMO business sales
- Increase in R&D expenditure¥101 million
- Increase in Share-Based Compensation Expense¥54 million
- Increase in non-operating income¥7 million
- Decrease in non-operating expenses¥-69 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- 主にCDMO事業の売上増加を予想
- 米国での治験開始に向けた前臨床試験費用の増加を予想
New initiatives
- スタンフォード大学との共同研究開始・動物実験開始
- FDAとのPre IND相談および海外治験申請準備
- カテーテル事業への本格参入と複数の開発プラン立ち上げ
- 朝日インテックとの共同研究開発
- 中之島クロスへの設備投資
- CDMO事業における新規取引先開拓
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2026 |
| Net Sales | ¥192 million |
| Operating profit | ¥-495 millions (operating loss) |
| Ordinary income | ¥-483 million (ordinary loss) |
| Net income | -483 Millions of yen (net loss attributable to owners of the parent) |
| Selling, general and administrative expenses | ¥610 million; selling, general and administrative expense ratio to revenue: not_disclosed |
| Full-year earnings forecast | Net Sales ¥590 million / Operating loss ¥-895 million / Ordinary loss ¥-883 million / Net loss attributable to owners of the parent ¥-889 million |
| Self-assessment against the plan | Progressing broadly in line with the plan |
| Breakdown of Factors Affecting the Change | Factors Increase in CDMO business sales / Amount Not disclosed, Factors Increase in R&D expenditure / Amount ¥101 million, Factors Increase in Share-Based Compensation Expense / Amount ¥54 million, Factors Increase in non-operating income / Amount ¥7 million, Factors Decrease in non-operating expenses / Amount ¥-69 million |
| Assumptions Underlying the Business Outlook | 主にCDMO事業の売上増加を予想, 米国での治験開始に向けた前臨床試験費用の増加を予想 |
| New initiatives | スタンフォード大学との共同研究開始・動物実験開始, FDAとのPre IND相談および海外治験申請準備, カテーテル事業への本格参入と複数の開発プラン立ち上げ, 朝日インテックとの共同研究開発, 中之島クロスへの設備投資, CDMO事業における新規取引先開拓 |
Items this document does not state (19)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.